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Abstract 
 
Von Hippel-Lindau (VHL) disease is a tumor syndrome that frequently involves the central 
nervous system (CNS). It is caused by germline mutation of the VHL gene. Subsequent VHL 
inactivation in selected cells is followed by numerous well-characterized molecular 
consequences, in particular, activation and stabilization of hypoxia-inducible factors HIF1 
and HIF2. The link between VHL gene inactivation and tumorigenesis remains poorly 
understood. Hemangioblastomas are the most common manifestation in the CNS; however, 
CNS invasion by VHL disease-associated endolymphatic sac tumors or metastatic renal 
cancer also occur, and their differentiation from primary hemangioblastoma may be 
challenging. Finally, in this review, we present recent morphologic insights on the 
developmental concept of VHL tumorigenesis which is best explained by pathologic 
persistence of temporary embryonic progenitor cells.  
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Introduction 
 
Von Hippel–Lindau (VHL) disease is an 
autosomal dominant disorder that is 
caused by germline mutations in the tumor 
suppressor gene VHL on chromosome 3p25 
(1, 2). It is characterized by frequent 
development of selective tumor types in 
specific topographic locations. Among 
others, central nervous system (CNS) 
hemangioblastoma and clear cell renal cell 
carcinoma (RCC) are the most consistently 
encountered tumors (3).  
 
Tumorigenesis in VHL syndrome is linked 
to the loss of VHL tumor suppressor 
protein function in cell differentiation (4-
7).The loss of protein function is the result 
of a second genetic “hit” which inactivates 
the wild type VHL allele (8). Subsequent to 
VHL gene inactivation and loss of VHL 
protein function, hypoxia-inducible factors 
(HIF1 and HIF2) are activated (9-11). HIF1 
is a heterodimer transcription factor 
composed of HIF1α and HIF1β subunits 
(12). Through conditional transcriptional 
activation of effectors controlling 
vascularization, glucose metabolism and 
cell differentiation, HIF1 plays an 
important role in cellular response to 
oxygen changes (12). HIF2α (also known as 
endothelial PAS domain-containing protein 
-1 (EPAS1)) is another hypoxia-inducible 
factor that functions as an integral 
component of transcription factors involved 
in the body response to low oxygen level 
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(13). In comparison to HIF1α which is 
expressed ubiquitously, HIF2α has a 
restricted tissue distribution and is 
expressed primarily in the vasculature of 
early developing embryo and subsequently 
in the lung, kidney interstitial cells, liver 
parenchyma, and neural crest cells (14). 
 
VHL protein is part of a multiprotein 
complex that targets HIFα subunits for 
ubiquitin-mediated degradation in 
proteasomes (11, 15-19). In hypoxic 
conditions or with VHL biallelic 
inactivation, both HIF1α and HIF2α 
subunits will evade degradation, 
accumulate in the cell and complex with 
other subunits to form functional proteins 
(9, 10, 20). The consequences of HIF1α and 
HIF2α up-regulation are multifaceted. One 
major change includes the transcriptional 
activation of genes containing hypoxia 
responsive elements. VEGF is among the 
target genes that will be overexpressed 
leading to enhanced angiogenesis and 
oxygen delivery (12, 21). Additionally, 
HIF2α up-regulation is linked to enhanced 
dysregulated erythropoiesis while HIF2α 
deletion has been shown to result in 
anemia associated with decreased 
expression of erythropoietin (22, 23). 
 
Despite the significant alterations at the 
cellular and molecular levels in association 
with VHL silencing, it has remained 
unclear, however, why loss of VHL function 
and subsequent HIF activation lead to 
tumorigenesis. Molecular and structural 
analogies of tumor cells with developmental 
tissues (6, 14, 24, 25) have led to 
revisitation of the hypothesis of a 
developmental origin of VHL disease-
associated tumors (26, 27). There is 
increasing evidence that the “second hit” 
causes loss of pivotal VHL function during 
organ development leading to maldeveloped 
structures that represent prerequisites for 
tumor formation (28). 
 
In VHL disease, the CNS is predominantly 
affected by hemangioblastic tumorigenesis, 
but may also be involved by endolymphatic 
sac tumors (ELST) or metastatic disease. 
 
Hemangioblastomas 
 
Hemangioblastomas of the nervous system 
are present in 80% of VHL patients and 
represent a defining feature of VHL 
syndrome (3, 29). Topographic distribution 
of these tumors show a consistent pattern 
with the retina, cerebellum, brainstem and 
dorsal spinal cord being the most 
frequently involved locations (3). With 
recent advancements in sensitive imaging 
techniques, there has been a shift in the 
distribution of these tumors with 
increasing proportion of spinal tumors in 
comparison to the pre MRI era (30). 
Supratentorial tumors represent less than 
3% of all tumors in most series (30, 31). In 
contrast to sporadic hemangioblastomas, 
VHL patients frequently have multiple 
hemangioblastomas, as is the case in 127 
out of 160 patients in one report (30). 
 
Clinical and radiological presentation 
 
Hemangioblastomas are benign tumors 
with no metastatic potential. However, as 
with other space occupying lesions of the 
brain, they may cause neurological deficit 
and carry a significant mortality rate if left 
untreated due to hydrocephalus, tonsillar 
herniation and brainstem compression (29, 
32). Not infrequently, these tumors have an 
associated pseudocyst or syrinx evident by 
magnetic resonance imaging (MRI) (33) 
(Figure 1). In addition to this cystic 
component, which may be much larger 
than the tumor itself, these tumors have a 
typical MRI appearance of densely 
contrast-enhancing solid mass with smooth 
margins (30, 34, 35). 
 
Pathological features 
 
The gross appearance of these tumors 
commonly shows a solid nodule with an 
associated pseudocyst. Pseudocysts result 
from secretory tumoral activity (33) and 
disappear after successful surgical removal 
of the tumoral nodule (33). The tumoral 
nodule is usually soft with bright or dark 
red color, and occasional yellow areas seen 
upon sectioning (28). Histological findings 
vary greatly and are dependent on tumor 
size (25). There are two main cellular 
constituents of hemangioblastomas, 
“stromal” cells and vascular cells. By 
selective genetic analysis, “stromal” cells 
have been shown to be neoplastic cells (36, 
37). The origin of the “stromal” cell has 
been controversial (38); however, most 
consistently proposed has been a 
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Figure 1. Radiological and histologic presentation of hemangioblastomas. A, T1-weighted postcontrast 
MR image shows right cerebellar hemangioblastoma (arrow) with an associated cyst (arrowheads); B, 
corresponding precontrast, fluid-attenuated inversion recovery, MR image demonstrating cyst 
hyperintensity (from Lonser et al., Ann Neurol 2005;58:392-399). C, Hemangioblastoma may present 
with mesenchymal (upper) and epitheloid structures (lower); Immunohistochemistry for vascular 
antigen CD34 reveals reactive vascularization (upper and lower right), neoplastic cells are negative for 
anti-CD34 (from Shively et al., J Pathol 2008;216:514-20).  
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hemangioblastic or hemangioblastic 
progenitor origin (27, 39-42). Since 
hemangioblasts were originally discovered 
in embryonal tissues almost 100 years ago 
(43-45) and are not known to exist in adult 
CNS tissue, the concept of a developmental 
origin of hemangioblastoma developed early 
(26, 27) and will be further discussed 
below. 
 
The second cellular constituent of 
hemangioblastoma is represented by 
abundant vascular cells that show no 
evidence of biallelic VHL inactivation and 
are therefore mostly – if not entirely – 
reactive (36, 46). The most plausible 
explanation for the abundance of reactive 
vascular structures in hemangioblastoma 
is the tumoral “stromal” cell expression of 
angiogenic factors (47). However, whether a 
subset of vascular structures may 
represent differentiation products of 
neoplastic hemangioblastic “stromal” cells 
(vasculogenesis) has been investigated with 
controversial results. 
 
Most immunohistochemical studies identify 
“stromal” cells and vascular cells as 
separate cytological constituents with no 
evidence of transition between the two cell 
types: they either report distinct 
immunoreactivity with different markers of 
interest (48-52) or find vascular markers 
factor VIII and/or factor XIIIa exclusively 
expressed in the vascular component of 
tumors (48, 53). In contrast, other studies 
reported expression of vascular markers in 
“stromal” cells (54-56). Cell culture studies 
either revealed no evidence of 
interconvertibility between endothelial cells 
and “stromal” cells (57) or evidence for 
vascular differentiation capacity of “stromal 
cells”(58). Microdissection studies revealed 
evidence for vasculogenesis in precursor 
structures of hemangioblastomas (59), but 
not in frank tumors (46). 
 
Within hemangioblastomas, the proportion 
of “stromal” and vascular cells can vary 
greatly and has been used as the basis of 
the traditional morphologic sub-
classification of hemangioblastoma into a 
vascular-rich reticular (also called 
“mesenchymal”) cell phenotype and a 
“stromal” cell-rich cellular (also called 
“epitheloid”) variant (60) (Figure 1). A 
study of 156 variably-sized 
hemangioblastomas revealed strong 
correlation between histologic subtype and 
tumor size (25). In the aforementioned 
study, all tumors smaller than 8 mm3 
showed exclusive reticular structure, also 
known as “angiomatotic”, or 
“mesenchymal”, that is characterized by 
small loosely scattered tumor cells 
separated by extensive vascularization (25). 
Larger tumors reveal additional phenotypic 
change, neoplastic stromal cells that are 
enlarged in size with abundant cytoplasm 
and large nuclei, and frequently clustered 
in groups (25).  Cytologically, the stromal 
cells in these latter neoplasms may have an 
abundant glycogen or lipid-rich cytoplasm 
imparting a clear appearance of the cell on 
routine H&E sections. Foci of 
extramedullary erythropoiesis can be 
detected in cellular (epitheloid) areas, but 
are not detected in reticular (mesenchymal) 
tumor portions. It has therefore been 
postulated that reticular lesions represent 
an earlier stage of tumorigenesis from 
which epitheloid tumor with 
extramedullary erythropoiesis may develop 
(25). Interestingly, these morphologic 
changes within individual 
hemangioblastomas have previously been 
interpreted as different stages of embryonic 
hemangioblastic maturation (40). 
 
Endolymphatic Sac Tumors 
 
The endolymphatic duct/sac system is 
composed of single-lumen thin long 
endolymphatic duct ending in a short 
pouch-like endolymphatic sac (61). The 
interior of this system is lined by single-
layered cuboidal endolymphatic duct/sac 
epithelium (62). The intraossesous part of 
the endolymphatic duct/sac system is also 
referred to as the vestibular aqueduct (63) 
and represents the site of origin of ELST 
(64). The endolymphatic duct/sac system is 
part of the nonsensory membranous 
labyrinth of the inner ear with a potential 
functional role in maintenance of 
homeostasis and pressure of the inner ear, 
phagocytosis of debris and immunologic 
functions (65-68). 
 
Epidemiology 
 
ELST was first established as a distinct 
pathologic entity by Heffner in 1989 (69). 
However, ELST had not been recognized as 
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Figure 2. Radiologic, morphologic and immunohistochemical features of ELSTs. Serial magnetic 
resonance (MR) and computed tomography (CT)-imaging of the temporal region from a VHL patient 
with hearing loss demonstrating the development of a left endolymphatic sac tumor. (A) Axial, T1-
weighted enhanced MR-imaging reveals enhancement in the region of the left endolymphatic duct 
(arrows).  (B) Corresponding, axial, non-enhanced, CT of the left temporal bone shows bony erosion 
confined to the left endolymphatic duct (arrowhead).  Morphologic spectrum of ELSTs: Papillary 
structures were observed in all tumors (C), whereas cystic areas (D) were seen in half of the cases.  
One tumor had areas of epitheloid clear cell clusters (E), reminiscent of clear cell renal carcinoma. 
Extensive hemosiderin deposits were evident in half of the tumors (F). A feature of all tumors was 
intensive vascularization (G, immunohistochemistry with anti-CD 34). Note the abundant vessels in 
papillary stroma (arrows) and the immediate contact of numerous small vessels with the cystic 
epithelium (arrowheads), which appears to be induced by expression of HIF and VEGF by the 
epithelial tumor cells. Immunohistochemistry for NSE (H), MAK6 (I) and AE1/AE3 (J) was 
consistently positive (from Glasker et al., Cancer Res 2005;65:10847-53).  
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a component tumor of VHL disease until 
1997, after the identification of 15 inner 
ear tumors in 13 out of 121 patients with 
VHL disease, while none of 253 patients 
without evidence of VHL disease had inner 
ear tumors (70). Additional studies 
documenting VHL inactivation by 
microdissection and PCR-based loss of 
heterozygosity analysis provided genetic 
and molecular confirmation of this 
association (64, 71, 72). Moreover, 
neoplastic cells were found to show 
activation of both HIF1and HIF2 as well as 
expression of CAIX and GLUT-1 which are 
downstream targets of HIF, and co-
expression of EPO and EPOR, which has 
been implicated in promotion of tumor 
growth (64, 73). The prevalence of ELST in 
VHL patients has been reported to be 
approximately 10% to 15% based on 
imaging studies, with 30% of these patients 
having bilateral tumors (74). 
 
Clinical presentation 
 
ELST can cause hearing loss, tinnitus, 
vertigo and facial nerve paresis (75). 
Hearing loss can occur in larger tumors 
with invasion of the otic capsule, but also 
in smaller tumors. The proposed 
mechanisms of hearing loss in these 
tumors include hemorrhage and/or 
endolymphatic hydrops (76, 77). 
 
Morphology 
 
ELSTs present grossly as bright or dark red 
soft tissue masses (76). The histological 
appearances of these tumors are variable 
and are usually composed of a mixture of 
three main architectural patterns; 
papillary, cystic and epithelioid clear cell 
(64, 69). One consistently observed feature 
is the presence of extensively vascularized 
papillary structures. These papillary 
structures are lined by a single row of 
cuboidal epithelial cells. Focal cystic 
growth can be observed in a subset of 
tumors as is focal clusters of epitheloid 
clear cell. The cysts have a single epithelial 
lining and frequently contain proteinaceous 
material. Mitotic figures are rare. Extensive 
hemosiderin deposits are common and 
associated with degenerative features 
including fibrosis, inflammation and 
cholesterol cleft formation (Figure 2). 
Immunohistochemical analysis of VHL 
disease-associated ELSTs reveals positive 
immunoreactivity with anti-NSE, anti-
MAK6, and anti-AE1/AE3 (64, 78). 
Immunohistochemistry for EMA and S100 
is positive in subsets of cases (79). Some 
sporadic tumors have also been reported to 
be positive for GFAP and vimentin (78). 
 
In addition to frank tumors, multifocal 
microscopic cystic and papillary structures 
were identified in the intra- and extra-
osseous endolymphatic duct/sac system in 
VHL patients (64). These structure were 
different in their molecular profile from 
similar cystic proliferations identified in 
non VHL patients; in VHL patients, the 
cystic and papillary structures showed loss 
of the wild-type VHL allele in addition to 
positive nuclear staining for HIF1 and HIF2 
and expression of target proteins CAIX and 
GLUT-1 (64, 80). It has been proposed that 
these structures represent tumor 
precursors (64). 
 
Metastasis 
 
Metastasis into the nervous system can 
occur from three different types of VHL 
disease-associated tumors. Most 
frequently, metastasis is caused by RCC 
which often may show striking 
resemblance to primary hemangioblastoma 
or ELST. Far less frequently observed are 
metastatic pheochromocytoma / 
paraganglioma or metastatic 
neuroendocrine tumors. 
 
Metastatic renal clear cell carcinoma 
 
Metastasis of RCC can occur anywhere 
within the nervous system. However, if 
metastasis occurs into cerebellum, 
brainstem, or spinal cord, differentiation 
from primary hemangioblastoma may 
constitute a diagnostic challenge. Both 
tumors share histologic features including 
cells with clear or vacuolated cytoplasm, 
extensive vascularization and occasional 
clustering of epitheloid cells. Additionally, 
both tumors share VHL gene deficiency as 
well as expression of VEGF, HIF, CAIX and 
other VHL target proteins. Several subtle 
morphological features have been proposed 
to help differentiate these tumors. Most 
importantly, cytoplasmic membranes are 
more distinct in renal cell carcinoma, while 
less well defined in hemangioblastoma 
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Figure 3. Metastatic RCC. Left, Metastatic renal cell carcinoma to brain resembling 
hemangioblastoma, H&E stain; right, immunohistochemistry for EMA shows characteristic 
membranous staining. 
 
 
cells. Also, identification of mitotic figures 
strongly favors metastatic renal cell 
carcinoma. Necrosis is virtually never seen 
in hemangioblastoma, unless tumors had 
been pretreated with radiation or 
embolization (28). 
 
Immunohistochemistry is a valuable tool to 
distinguish hemangioblastoma from 
metastatic RCC. Epithelial membrane 
antigen (EMA) was originally described to 
selectively identify RCC (81, 82). However, 
focal expression of EMA may rarely occur 
in hemangioblastoma (83) (Figure 3). Anti-
inhibin A showed a high sensitivity and 
specificity for hemangioblastoma in one 
study (84). Other potentially useful 
markers include anti-CD10 for the 
identification of RCC and D2-40 and 
aquaporin-1 for the selective identification 
of hemangioblastoma (85-88). More 
recently, a combination of PAX-2 and PAX8 
(positive in RCC) and inhibin A (positive in 
hemangioblastoma) has been proposed as 
the most useful panel of markers to resolve 
this differential diagnosis (89). Another 
important role of immunohistochemistry is 
the identification tumor heterogeneity that 
is caused by tumor metastasis into 
hemangioblastoma which is being reported 
in up to 8% of hemangioblastomas (90, 91). 
 
 
VHL tumorigenesis 
 
Development of tumors in VHL disease– 
Arvid Lindau’s hypothesis 
 
Decades ago, the hypothesis of a 
hemangioblastic nature of CNS tumors in 
VHL disease fueled an even older debate on 
the origin of cancer which notably has not 
been settled until today. In the early and 
mid-1800s, Joseph Recamier and Robert 
Remak both noted that cancer tissue 
resembled embryonic tissue (92). In 1874-
1875 Francesco Durante and Julius 
Cohnheim proposed cancer to originate 
from small collections of embryonal cells 
that persist and do not differentiate into 
mature adult tissue (92-94). In the early 
1900s, this theory was rejected (92, 95, 
96). When, however, Arvid Lindau 
discovered and described in detail the gross 
and histologic changes of VHL disease, he 
came to the conclusion that “…all types of 
neoplasia might be explained by a 
disturbed balance during mesodermal 
development during the third month of 
embryonal life” (26). While Arvid Lindau 
was therefore a strong supporter of the 
“embryonic rest”-hypothesis to explain CNS 
tumorigenesis in VHL disease, he 
subsequently noted that “an underlying 
early maldevelopment” may give rise to two 
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Figure 4. Developmentally arrested structural elements (DASEs), incidentally discovered in grossly 
normal-appearing nerve root tissue of VHL patients by histologic analysis of random spinal cord 
sections obtained at autopsy (from Vortmeyer et al., Ann. Neurol. 2004; 55:721-728). All depicted 
DASEs were present intradurally in different nerve roots. All lesions reveal circumscribed 
accumulations of persistent embryonal VHL-deficient hemangioblast progenitor cells (see references 
24 and 98). A, cross-section of a nerve root, filled with embryonal cells; B, The central portion of the 
root shows an accumulation of embryonal cells which is sharply demarcated from surrounding 
normal root tissue; C, A longitudinal nerve root section reveals frequently observed longitudinal 
extension of DASE’s along fiber tracts; D, intraradicular DASE with embryonal cells, diffusely 
scattered around neurites; E, DASE, selectively involving a central nerve root fascicle; F, 
circumscribed DASE in nerve root; focal clear cell phenotype and early multifocal vascular perfusion 
may indicate early progression into hemangioblastoma. 
 
  
 
different pathologic processes 
“Hemangioblastoma” and “capillary 
angiomatosis” (27). He was, however, 
unable to explain how “early 
maldevelopment” can produce such 
extreme neoplastic diversity: a tumor 
composed of hemangioblastic cells on one 
hand, and a tumor composed of mature 
vascular cells on the other. 
 
Lindau’s hypothesis – analytical and 
experimental evidence 
 
More recently, we worked on a resolution of 
this seemingly contradictory nature of VHL 
disease-associated CNS tumors. Key 
strategy for this effort was to change the 
primary target of histologic analysis. 
Instead of analyzing tumor tissues, we 
analyzed normal-appearing tissues of VHL 
patients in which tumors are known to  
 
frequently occur, spinal cord and 
cerebellum. 
 
The study of tumor-free central and 
peripheral nervous system tissue of VHL 
patients revealed numerous microscopic 
structures that are not encountered in 
similar tissues of non-VHL control patients 
(24, 64, 97, 98) (Figure 4). In essence, 
these structures represent the “early 
embryonal maldevelopment” postulated by 
Lindau and have hence been designated 
“developmentally arrested structural 
elements” (DASEs) (97). DASEs represent 
precursors of CNS tumors in VHL disease; 
however, only a small number of DASEs 
progress to frank tumor during the lifetime 
of a VHL patient (24, 25, 97). 
 
The key constituent of DASEs are small 
primitive VHL-deficient cells that 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.             http://jkcvhl.com 122 
 
apparently represent immature 
hemangioblast progenitor cells, 
accompanied by reactive vasculature (24, 
97, 98) (Figure 4). Early tumor arising 
from DASEs is highly vascularized and 
resembles “angiomatosis”. Upon further 
tumor growth, tumor cells increase in size, 
develop epitheloid architecture and may 
differentiate in blood (25, 42, 58). The 
morphologic sequence of tumorigenesis 
from DASEs to frank tumor reveals 
transition of mesenchymal cells into 
epitheloid structures and thus explains the 
diverse and complex histologic presentation 
of CNS tumor in VHL disease. 
 
According to Knudson’s two hit hypothesis, 
tumorigenesis in VHL disease is initiated 
by the “second hit”, inactivation of the wild 
type copy of the VHL allele in patients that 
carry the VHL mutation (8). The recent 
identification of numerous VHL-deficient 
DASEs in tumor-free CNS tissues of VHL 
patients led to the conclusion that the 
“second hit” is necessary, but insufficient 
for tumorigenesis (98, 99). Instead, “second 
hits” appear to be capable of producing 
DASEs from which frank tumors may or 
may not develop. The nature of the third 
hit allowing DASEs to develop into frank 
tumor remains unknown. 
 
Persistence of temporary embryonal 
progenitor cells 
 
In VHL disease, the embryonal rest 
hypothesis does not necessarily imply the 
generation of neoplastic tissue during 
organ development. Instead, it implies the 
causative genetic hit to occur during organ 
development with the effect of 
developmental arrest of variable numbers 
of embryonal/fetal cells that have the 
capacity of eventual neoplastic 
proliferation. Key arguments are: 
 
a) Organ selectivity: Precursor and tumor 
formation occurs abundantly in selective 
tissue structures, and not at all in others; 
In VHL disease, there is dramatically 
increased risk of development of 
hemangioblastoma, renal clear cell 
carcinoma, cystadenoma of pancreas and 
endolymphatic sac, and neuroendocrine 
tumors, but no increased risk for any other 
type of cancer. 
 
b) Tumor specificity: While large varieties of 
different tumors are known to exist in CNS 
and kidney, only tumors with specific 
histology occur in affected organs. 
 
c) Consistent topographic distribution of 
precursor structures/tumors: Tissue 
development is strongly associated with 
pattern formation. VHL disease not only 
targets the nervous system, it does so in a 
near-predictable pattern of distribution. 
Neoplastic structures are frequently 
observed in spinal cord and cerebellum, 
only rarely in cerebrum. Within the 
cerebellum, the molecular layer is primarily 
affected. In spinal cord tissue, 
precursors/tumors are detected far more 
frequently in dorsal than in ventral roots. 
The most frequently affected specific 
topographic CNS site is the obex of the 
brainstem (E. Oldfield, personal 
communication). 
 
d) Stem/progenitor cell properties of VHL 
deficient neoplastic cells: Multiple different 
analytic and/or experimental approaches 
have identified the VHL-deficient neoplastic 
cell as primitive hemangioblastic progenitor 
cell with capacity of differentiation into red 
blood cells and/or primitive vascular 
structures. Although not definitively 
demonstrated, there is strong supportive 
evidence for hemangioblastic differentiation 
to occur during brain (and even stronger 
evidence for kidney) development. 
Hemangioblastic cells are not part of the 
mature nervous system; instead, 
hemangioblastic cells persist in the 
nervous system due to pathologic events 
during tissue development and represent a 
condicio sine qua non for tumor 
development. 
 
Alternative hypotheses 
 
Alternative hypotheses for tumor 
development include a) tumorigenesis from 
a pre-existent glial, neuronal, or 
mesenchymal cell (100); b) tumorigenesis 
from circulating cells (101); c) 
tumorigenesis from a stem cell (96, 102, 
103). 
 
a) Tumorigenesis from a pre-existent cell in 
the nervous system would imply 
dedifferentiation of mature cells into 
hemangioblastic progenitor cells which not 
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only has never been demonstrated, but 
should be expected to be an extraordinarily 
complex molecular and structural process. 
Activation of HIF occurs in tissues under 
hypoxic stress, but is not known to be 
related to tumorigenesis. Structural 
analysis of precursor/tumor structures in 
the nervous system reveal the pathology to 
evolve from minute poorly differentiated 
foci into larger lesions with increased 
maturation (24), with erythropoiesis 
occurring only in largest-sized frank 
tumors (25). Simply, the abundance of 
minute structural changes in VHL tissues 
is explained more easily by an origin from 
VHL-deficient aberrant cells; furthermore, 
the most frequent occurrence of precursor 
structures in nerve root tissue provides a 
very limited set of candidate cells for tumor 
development. 
 
b) Circulating bone marrow cells have been 
implicated in the generation of or 
contribution to brain tumors (101). This 
hypothesis would explain tumor specificity, 
but require bone marrow hematopoietic 
cells to be primarily targeted by the second 
hit. The VHL deficient hemangioblastic 
progenitor/stem cell is the most primitive 
form of hemangioblast, originally 
discovered in the yolk sac (45). To support 
this hypothesis, it would be necessary to 
demonstrate presence of these primitive 
hemangioblastic precursor cells in fetal or 
adult bone marrow. More difficult to 
explain, however, would be the principles of 
organ selectivity and topographic 
distribution of VHL tumors. In addition, 
bone marrow pathology is not known to 
exist in VHL disease. 
 
c) Since VHL deficient tumor cells in 
nervous system have been identified as 
hemangioblastic progenitor cells, an origin 
from VHL-deficient stem cells with 
hemangioblastic differentiation potential 
certainly deserves consideration. While the 
role of stem cells in the brain remains 
controversial, a stem cell origin of brain 
(and many other) tumors is being 
increasingly accepted (103). By definition, 
stem cells are totipotent cells with 
differentiation potential along multiple (in 
the brain along astrocytic, oligodendroglial 
and neuronal) cell lineages which is not the 
case in VHL disease (tumor specificity). 
Nevertheless, while the pathogenic cell in 
VHL nervous system remains best-
characterized as VHL-deficient 
hemangioblastic progenitor cell, the second 
hit could occur in a totipotent stem cell, 
with VHL inactivation being exclusively 
permissive for hemangioblastic 
differentiation. However, the stem cell 
hypothesis fails to explain organ selectivity 
and consistent topographical lesion 
distribution within organs. Also, 
experimental knock-out of the VHL gene in 
cell systems has so far not revealed 
evidence for hemangioblastic 
differentiation. 
 
In essence, stem cell hypothesis and 
embryonal rest hypothesis are not entirely 
exclusive.  Like hematopoietic progenitor 
cells, stem cells are derived from embryonal 
cells. The key difference is the time of the 
second hit, VHL inactivation. The stem cell 
theory would allow for the second hit to 
occur any time, while the embryonic rest 
hypothesis postulates the second hit to 
occur early during tissue development, 
producing an early and pathologic set of 
VHL deficient hemangioblastic progenitor 
cells. It is the embryonic rest hypothesis 
which most comfortably explains the key 
arguments presented above. 
 
This modified embryonal rest hypothesis 
has not been proven, but it most 
effortlessly explains clinical, pathologic and 
experimental evidence available so far. 
Similarly effortlessly it can be applied to 
any other classic tumor suppressor gene 
syndrome (e.g. MEN1, neurofibromatosis), 
with confirmatory literature on record. 
Thus, VHL disease is a naturally occurring 
human tumor suppressor gene “model” the 
unique features of which give insight into 
the biology of neoplastic disease and 
cancer. 
 
Conclusion 
 
VHL disease is a classic tumor suppressor 
gene syndrome caused by VHL gene 
germline mutation. In the nervous system, 
the “second hit” - VHL wild-type gene 
inactivation – induces DASEs which have 
the potential to develop into benign 
hemangioblastic tumors. In the kidney, 
VHL-deficient cells give rise to renal clear 
cell carcinoma which can metastasize into 
brain and spinal cord. Endolymphatic sac 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.             http://jkcvhl.com 124 
 
tumors may develop in the vestibular 
aqueduct with the potential of brain 
invasion. While the molecular 
consequences of VHL inactivation have 
been worked out in detail, fundamental 
questions have remained unexplained by 
these studies. The fundamental questions 
include organ selectivity, tumor specificity, 
the consistent lesional distribution pattern, 
and the embryonal/stem cell nature of the 
tumor cells. These intriguing features are 
best explained by the “second hit” 
occurring during nervous system 
development. Application of this concept 
may generate new research approaches to 
VHL-deficient tumors, their sporadic 
counterparts as well as tumors in the 
context of other tumor suppressor gene 
syndromes. 
 
Acknowledgements 
 
Many thanks to Dr. Douglas Brash for 
numerous fruitful scientific discussions. 
 
References 
 
1. Kaelin WG Jr. Molecular basis of the VHL 
hereditary cancer syndrome. Nat Rev Cancer. 
2002;2(9):673-82. 
http://dx.doi.org/10.1038/nrc885 
 
2. Latif F et al. Identification of the von Hippel-
Lindau disease tumor suppressor gene. Science. 
1993;260(5112):1317-20. 
http://dx.doi.org/10.1126/science.8493574 
 
3. Lonser RR, Glenn GM, Walther M, Chew EY, 
Libutti SK, Linehan WM, Oldfield EH. von 
Hippel-Lindau disease. Lancet. 
2003;361(9374):2059-67. 
http://dx.doi.org/10.1016/S0140-
6736(03)13643-4 
 
4. Haase VH. The VHL tumor suppressor in 
development and disease: functional studies in 
mice by conditional gene targeting. Semin Cell 
Dev Biol. 2005;16(4-5):564-74. 
http://dx.doi.org/10.1016/j.semcdb.2005.03.0
06 
 
5. Gnarra JR, Ward JM, Porter FD, Wagner JR, 
Devor DE, Grinberg A, Emmert-Buck MR, 
Westphal H, Klausner RD, Linehan WM. 
Defective placental vasculogenesis causes 
embryonic lethality in VHL-deficient mice. Proc 
Natl Acad Sci U S A. 1997;94(17):9102-7. 
http://dx.doi.org/10.1073/pnas.94.17.9102 
 
6. Mack FA, Rathmell WK, Arsham AM, Gnarra 
J, Keith B, Simon MC. Loss of pVHL is sufficient 
to cause HIF dysregulation in primary cells but 
does not promote tumor growth. Cancer Cell. 
2003;3(1):75-88. 
http://dx.doi.org/10.1016/S1535-
6108(02)00240-4 
 
7. Nyhan MJ, O'Sullivan GC, McKenna SL. Role 
of the VHL (von Hippel-Lindau) gene in renal 
cancer: a multifunctional tumour suppressor. 
Biochem Soc Trans. 2008;36(Pt 3):472-8. 
http://dx.doi.org/10.1042/BST0360472 
 
8. Knudson AG. Hereditary cancer: two hits 
revisited. J Cancer Res Clin Oncol. 
1996;122(3):135-40. 
http://dx.doi.org/10.1007/BF01366952 
 
9. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, 
Goldberg MA. Negative regulation of hypoxia-
inducible genes by the von Hippel-Lindau 
protein. Proc Natl Acad Sci U S A. 
1996;93(20):10595-9. 
http://dx.doi.org/10.1073/pnas.93.20.10595 
 
10. Krieg M, Haas R, Brauch H, Acker T, 
Flamme I, Plate KH. Up-regulation of hypoxia-
inducible factors HIF-1alpha and HIF-2alpha 
under normoxic conditions in renal carcinoma 
cells by von Hippel-Lindau tumor suppressor 
gene loss of function. Oncogene. 
2000;19(48):5435-43. 
http://dx.doi.org/10.1038/sj.onc.1203938 
 
11. Maxwell PH, Wiesener MS, Chang GW, 
Clifford SC, Vaux EC, Cockman ME, Wykoff CC, 
Pugh CW, Maher ER, Ratcliffe PJ. The tumour 
suppressor protein VHL targets hypoxia-
inducible factors for oxygen-dependent 
proteolysis. Nature. 1999;399(6733):271-5. 
http://dx.doi.org/10.1038/20459 
 
12. Semenza GL. Targeting HIF-1 for cancer 
therapy. Nat Rev Cancer. 2003;3(10):721-32. 
http://dx.doi.org/10.1038/nrc1187 
 
13. Tian H, McKnight SL, Russell DW. 
Endothelial PAS domain protein 1 (EPAS1), a 
transcription factor selectively expressed in 
endothelial cells. Genes Dev. 1997;11(1):72-82. 
http://dx.doi.org/10.1101/gad.11.1.72 
 
14. Simon MC, Keith B. The role of oxygen 
availability in embryonic development and stem 
cell function. Nat Rev Mol Cell Biol. 
2008;9(4):285-96. 
http://dx.doi.org/10.1038/nrm2354 
 
15. Lisztwan J, Imbert G, Wirbelauer C, 
Gstaiger M, Krek W. The von Hippel-Lindau 
tumor suppressor protein is a component of an 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome 
 
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.       http://jkcvhl.com  125 
 
E3 ubiquitin-protein ligase activity. Genes Dev. 
1999;13(14):1822-33. 
http://dx.doi.org/10.1101/gad.13.14.1822 
 
16. Lonergan KM, Iliopoulos O, Ohh M, Kamura 
T, Conaway RC, Conaway JW, Kaelin WG Jr. 
Regulation of hypoxia-inducible mRNAs by the 
von Hippel-Lindau tumor suppressor protein 
requires binding to complexes containing 
elongins B/C and Cul2. Mol Cell Biol. 
1998;18(2):732-41. 
 
17. Pause A, Lee S, Worrell RA, Chen DY, 
Burgess WH, Linehan WM, Klausner RD. The 
von Hippel-Lindau tumor-suppressor gene 
product forms a stable complex with human 
CUL-2, a member of the Cdc53 family of 
proteins. Proc Natl Acad Sci U S A. 
1997;94(6):2156-61. 
http://dx.doi.org/10.1073/pnas.94.6.2156 
 
18. Cockman ME, Masson N, Mole DR, Jaakkola 
P, Chang GW, Clifford SC, Maher ER, Pugh CW, 
Ratcliffe PJ, Maxwell PH. Hypoxia inducible 
factor-alpha binding and ubiquitylation by the 
von Hippel-Lindau tumor suppressor protein. J 
Biol Chem. 2000;275(33):25733-41. 
http://dx.doi.org/10.1074/jbc.M002740200 
 
19. Ohh M, Park CW, Ivan M, Hoffman MA, Kim 
TY, Huang LE, Pavletich N, Chau V, Kaelin WG. 
Ubiquitination of hypoxia-inducible factor 
requires direct binding to the beta-domain of 
the von Hippel-Lindau protein. Nat Cell Biol. 
2000;2(7):423-7. 
http://dx.doi.org/10.1038/35017054 
 
20. Jiang BH, Zheng JZ, Leung SW, Roe R, 
Semenza GL. Transactivation and inhibitory 
domains of hypoxia-inducible factor 1alpha. 
Modulation of transcriptional activity by oxygen 
tension. J Biol Chem. 1997;272(31):19253-60. 
http://dx.doi.org/10.1074/jbc.272.31.19253 
 
21. Ema M, Taya S, Yokotani N, Sogawa K, 
Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-
PAS factor with close sequence similarity to 
hypoxia-inducible factor 1alpha regulates the 
VEGF expression and is potentially involved in 
lung and vascular development. Proc Natl Acad 
Sci U S A. 1997;94(9):4273-8. 
http://dx.doi.org/10.1073/pnas.94.9.4273 
 
22. Rankin EB, Biju MP, Liu Q, Unger TL, Rha 
J, Johnson RS, Simon MC, Keith B, Haase VH. 
Hypoxia-inducible factor-2 (HIF-2) regulates 
hepatic erythropoietin in vivo. J Clin Invest. 
2007;117(4):1068-77. 
http://dx.doi.org/10.1172/JCI30117 
 
23. Gruber M, Hu CJ, Johnson RS, Brown EJ, 
Keith B, Simon MC. Acute postnatal ablation of 
Hif-2alpha results in anemia. Proc Natl Acad Sci 
U S A. 2007;104(7):2301-6. 
http://dx.doi.org/10.1073/pnas.0608382104 
 
24. Vortmeyer AO et al. Evolution of VHL 
tumourigenesis in nerve root tissue. J Pathol. 
2006 Nov;210(3):374-82. 
http://dx.doi.org/10.1002/path.2062 
 
25. Shively SB, Beltaifa S, Gehrs B, Duong H, 
Smith J, Edwards NA, Lonser R, Raffeld M, 
Vortmeyer AO. Protracted haemangioblastic 
proliferation and differentiation in von Hippel-
Lindau disease. J Pathol. 2008;216(4):514-20. 
http://dx.doi.org/10.1002/path.2435 
 
26. Lindau A. Studien über Kleinhirncysten. 
Bau, Pathogenese und Beziehungen zur 
Angiomatosis retinae. Copenhagen; 1926. 
 
27. Lindau A. Discussion on vascular tumors of 
the brain and spinal cord. Proc R Soc Med. 
1931; 24: 363. 
 
28. Vortmeyer AO, Falke EA, Glasker S, Li J, 
Oldfield EH. Nervous system involvement in von 
Hippel-Lindau disease: pathology and 
mechanisms. Acta Neuropathol. 
2013;125(3):333-50. 
http://dx.doi.org/10.1007/s00401-013-1091-z 
 
29. Maher ER, Yates JR, Harries R, Benjamin C, 
Harris R, Moore AT, Ferguson-Smith MA. 
Clinical features and natural history of von 
Hippel-Lindau disease. Q J Med. 
1990;77(283):1151-63. 
http://dx.doi.org/10.1093/qjmed/77.2.1151 
 
30. Wanebo JE, Lonser RR, Glenn GM, Oldfield 
EH. The natural history of hemangioblastomas 
of the central nervous system in patients with 
von Hippel-Lindau disease. J Neurosurg. 
2003;98(1):82-94. 
http://dx.doi.org/10.3171/jns.2003.98.1.0082 
 
31. Grisoli F, Gambarelli D, Raybaud C, 
Guibout M, Leclercq T. Suprasellar 
hemangioblastoma. Surg Neurol. 
1984;22(3):257-62. 
http://dx.doi.org/10.1016/0090-
3019(84)90010-7 
 
32. Neumann HP, Eggert HR, Weigel K, 
Friedburg H, Wiestler OD, Schollmeyer P. 
Hemangioblastomas of the central nervous 
system. A 10-year study with special reference 
to von Hippel-Lindau syndrome. J Neurosurg. 
1989;70(1):24-30. 
http://dx.doi.org/10.3171/jns.1989.70.1.0024 
 
33. Lonser RR, Vortmeyer AO, Butman JA, 
Glasker S, Finn MA, Ammerman JM, Merrill MJ, 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.             http://jkcvhl.com 126 
 
Edwards NA, Zhuang Z, Oldfield EH. Edema is a 
precursor to central nervous system peritumoral 
cyst formation. Ann Neurol. 2005;58(3):392-9. 
http://dx.doi.org/10.1002/ana.20584 
 
34. Resche F, Moisan JP, Mantoura J, de 
Kersaint-Gilly A, Andre MJ, Perrin-Resche I, 
Menegalli-Boggelli D, Lajat Y, Richard S. 
Haemangioblastoma, haemangioblastomatosis, 
and von Hippel-Lindau disease. Adv Tech Stand 
Neurosurg. 1993;20:197-304. 
http://dx.doi.org/10.1007/978-3-7091-6912-
4_6 
 
35. Filling-Katz MR et al. Central nervous 
system involvement in Von Hippel-Lindau 
disease. Neurology. 1991;41(1):41-6.  
http://dx.doi.org/10.1212/WNL.41.1.41 
 
36. Vortmeyer AO, Gnarra JR, Emmert-Buck 
MR, Katz D, Linehan WM, Oldfield EH, Zhuang 
Z. von Hippel-Lindau gene deletion detected in 
the stromal cell component of a cerebellar 
hemangioblastoma associated with von Hippel-
Lindau disease. Hum Pathol. 1997;28(5):540-3. 
http://dx.doi.org/10.1016/S0046-
8177(97)90075-7 
 
37. Lee JY et al. Loss of heterozygosity and 
somatic mutations of the VHL tumor suppressor 
gene in sporadic cerebellar hemangioblastomas. 
Cancer Res. 1998;58(3):504-8. 
 
38. Plate K. H. VAO, Zagzag D., Neumann 
H.P.H. Familial Tumour Syndromes involving 
the Nervous System. In: Louis DN, ed. WHO 
classification of tumours of the central nervous 
system: World Health Organization (WHO), 
2007. 
 
39. Cushing H BP. Tumors Arising from the 
Blood-Vessels of the Brain. Angiomatous 
Malformations and Hemangioblastomas. In: 
Thomas CC, ed. Springfield, 1928. 
 
40. Stein AA, Schilp AO, Whitfield RD. The 
histogenesis of hemangioblastoma of the brain. 
A review of twenty-one cases. J Neurosurg. 
1960;17:751-61. 
http://dx.doi.org/10.3171/jns.1960.17.4.0751 
 
41. Gläsker S, Li J, Xia JB, Okamoto H, Zeng W, 
Lonser RR, Zhuang Z, Oldfield EH, Vortmeyer 
AO. Hemangioblastomas share protein 
expression with embryonal hemangioblast 
progenitor cell. Cancer Res. 2006;66(8):4167-
72. 
http://dx.doi.org/10.1158/0008-5472.CAN-05-
3505 
 
42. Vortmeyer AO et al. Developmental arrest of 
angioblastic lineage initiates tumorigenesis in 
von Hippel-Lindau disease. Cancer Res. 
2003;63(21):7051-5. 
 
43. Sabin FR. Preliminary note on the 
differentiation of angioblasts and the method by 
which they produce blood-vessels, blood-plasma 
and red blood-cells as seen in the living chick. 
1917. J Hematother Stem Cell Res. 
2002;11(1):5-7. 
http://dx.doi.org/10.1089/1525816027534484
96 
 
44. Sabin FR. Studies on the origin of the blood 
vessels and of red blood corpuscles as seen in 
the living blastoderm of chick during the second 
day of incubation. Carnegie Contrib Embryol. 
1920; 9: 215. 
 
45. Sabin FR. Preliminary note on the 
differentiation of angioblasts and the method by 
which they produce blood-vessels, blood-plasma 
and red blood-cells as seen in the living chick. 
Anat Rec. 1917; 13: 199. 
http://dx.doi.org/10.1002/ar.1090130403 
 
46. Glasker S, Smith J, Raffeld M, Li J, Oldfield 
EH, Vortmeyer AO. VHL-deficient 
vasculogenesis in hemangioblastoma. Exp Mol 
Pathol. 2014;96(2):162-7. 
http://dx.doi.org/10.1016/j.yexmp.2013.12.01
1 
 
47. Wizigmann-Voos S, Breier G, Risau W, Plate 
KH. Up-regulation of vascular endothelial 
growth factor and its receptors in von Hippel-
Lindau disease-associated and sporadic 
hemangioblastomas. Cancer Res. 
1995;55(6):1358-64. 
 
48. Tanimura A, Nakamura Y, Hachisuka H, 
Tanimura Y, Fukumura A. Hemangioblastoma 
of the central nervous system: nature of the 
stromal cells as studied by the 
immunoperoxidase technique. Hum Pathol. 
1984;15(9):866-9. 
http://dx.doi.org/10.1016/S0046-
8177(84)80148-3 
 
49. Becker I, Paulus W, Roggendorf W. 
Histogenesis of stromal cells in cerebellar 
hemangioblastomas. An immunohistochemical 
study. Am J Pathol. 1989;134(2):271-5. 
 
50. Frank TS, Trojanowski JQ, Roberts SA, 
Brooks JJ. A detailed immunohistochemical 
analysis of cerebellar hemangioblastoma: an 
undifferentiated mesenchymal tumor. Mod 
Pathol. 1989;2(6):638-51. 
 
51. Nemes Z. Fibrohistiocytic differentiation in 
capillary hemangioblastoma. Hum Pathol. 
1992;23(7):805-10. 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome 
 
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.       http://jkcvhl.com  127 
 
http://dx.doi.org/10.1016/0046-
8177(92)90351-3 
 
52. Kamitani H, Masuzawa H, Sato J, Kanazawa 
I. Capillary hemangioblastoma: histogenesis of 
stromal cells. Acta Neuropathol. 
1987;73(4):370-8. 
http://dx.doi.org/10.1007/BF00688262 
 
53. Cruz-Sanchez FF, Rossi ML, Rodriguez-
Prados S, Nakamura N, Hughes JT, Coakham 
HB. Haemangioblastoma: histological and 
immunohistological study of an enigmatic 
cerebellar tumour. Histol Histopathol. 
1990;5(4):407-13. 
 
54. Jurco S 3rd, Nadji M, Harvey DG, Parker JC 
Jr, Font RL, Morales AR. Hemangioblastomas: 
histogenesis of the stromal cell studied by 
immunocytochemistry. Hum Pathol. 
1982;13(1):13-8. 
http://dx.doi.org/10.1016/S0046-
8177(82)80133-0 
 
55. Omulecka A, Lach B, Alwasiak J, Gregor A. 
Immunohistochemical and ultrastructural 
studies of stromal cells in hemangioblastoma. 
Folia Neuropathol. 1995;33(1):41-50. 
 
56. Lach B, Gregor A, Rippstein P, Omulecka A. 
Angiogenic histogenesis of stromal cells in 
hemangioblastoma: ultrastructural and 
immunohistochemical study. Ultrastruct Pathol. 
1999;23(5):299-310. 
http://dx.doi.org/10.1080/019131299281446 
 
57. Spence AM, Rubinstein LJ. Cerebellar 
capillary hemangioblastoma: its histogenesis 
studied by organ culture and electron 
microscopy. Cancer. 1975;35(2):326-41. 
http://dx.doi.org/10.1002/1097-
0142(197502)35:2<326::AID-
CNCR2820350206>3.0.CO;2-8 
 
58. Park DM et al. von Hippel-Lindau disease-
associated hemangioblastomas are derived from 
embryologic multipotent cells. PLoS Med. 
2007;4(2):e60. 
http://dx.doi.org/10.1371/journal.pmed.00400
60 
 
59. Zhuang Z, Frerich JM, Huntoon K, Yang C, 
Merrill MJ, Abdullaev Z, Pack SD, Shively SB, 
Stamp G, Lonser RR. Tumor derived 
vasculogenesis in von Hippel-Lindau disease-
associated tumors. Sci Rep. 2014;4:4102. 
http://dx.doi.org/10.1038/srep04102 
 
60. Hasselblatt M, Jeibmann A, Gerss J, 
Behrens C, Rama B, Wassmann H, Paulus W. 
Cellular and reticular variants of 
haemangioblastoma revisited: a 
clinicopathologic study of 88 cases. Neuropathol 
Appl Neurobiol. 2005;31(6):618-22. 
http://dx.doi.org/10.1111/j.1365-
2990.2005.00669.x 
 
61. Netter FH CS. Atlas of Human Anatomy. 
Summit: Ciba Geigy Corporation, 1989. 
PMCid:PMC1003780 
 
62. Lo WW, Daniels DL, Chakeres DW, 
Linthicum FH Jr, Ulmer JL, Mark LP, Swartz 
JD. The endolymphatic duct and sac. AJNR Am 
J Neuroradiol. 1997;18(5):881-7. 
 
63. Arenberg IK, Rask-Andersen H, Wilbrand H, 
Stahle J. The surgical anatomy of the 
endolymphatic sac. Arch Otolaryngol. 
1977;103(1):1-11. 
http://dx.doi.org/10.1001/archotol.1977.0078
0180039001 
 
64. Gläsker S, Lonser RR, Tran MG, Ikejiri B, 
Butman JA, Zeng W, Maxwell PH, Zhuang Z, 
Oldfield EH, Vortmeyer AO. Effects of VHL 
deficiency on endolymphatic duct and sac. 
Cancer Res. 2005;65(23):10847-53. 
http://dx.doi.org/10.1158/0008-5472.CAN-05-
1104 
 
65. Wackym PA1, Glasscock ME 3rd, Linthicum 
FH Jr, Friberg U, Rask-Andersen H. 
Immunohistochemical localization of Na+, K+-
ATPase in the human endolymphatic sac. Arch 
Otorhinolaryngol. 1988;245(4):221-3. 
http://dx.doi.org/10.1007/BF00463931 
 
66. Morgenstern C, Amano H, Orsulakova A. Ion 
transport in the endolymphatic space. Am J 
Otolaryngol. 1982;3(5):323-7. 
http://dx.doi.org/10.1016/S0196-
0709(82)80004-5 
 
67. Erwall C, Friberg U, Bagger-Sjoback D, 
Rask-Andersen H. Degradation of the 
homogeneous substance in the endolymphatic 
sac. Acta Otolaryngol. 1988;105(3-4):209-17. 
http://dx.doi.org/10.3109/0001648880909700
0 
 
68. Harris JP. Autoimmunity of the inner ear. 
Am J Otol. 1989;10(3):193-5. 
 
69. Heffner DK. Low-grade adenocarcinoma of 
probable endolymphatic sac origin A 
clinicopathologic study of 20 cases. Cancer. 
1989;64(11):2292-302. 
http://dx.doi.org/10.1002/1097-
0142(19891201)64:11<2292::AID-
CNCR2820641119>3.0.CO;2-# 
 
70. Manski TJ et al. Endolymphatic sac tumors. 
A source of morbid hearing loss in von Hippel-
Lindau disease. JAMA. 1997;277(18):1461-6. 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.             http://jkcvhl.com 128 
 
http://dx.doi.org/10.1001/jama.1997.0354042
0057030 
 
71. Kawahara N, Kume H, Ueki K, Mishima K, 
Sasaki T, Kirino T. VHL gene inactivation in an 
endolymphatic sac tumor associated with von 
Hippel-Lindau disease. Neurology. 
1999;53(1):208-10. 
http://dx.doi.org/10.1212/WNL.53.1.208 
 
72. Vortmeyer AO, Choo D, Pack SD, Oldfield E, 
Zhuang Z. von Hippel-Lindau disease gene 
alterations associated with endolymphatic sac 
tumor. J Natl Cancer Inst. 1997;89(13):970-2. 
http://dx.doi.org/10.1093/jnci/89.13.970-a 
 
73. Vogel TW, Vortmeyer AO, Lubensky IA, Lee 
YS, Furuta M, Ikejiri B, Kim HJ, Lonser RR, 
Oldfield EH, Zhuang Z. Coexpression of 
erythropoietin and its receptor in endolymphatic 
sac tumors. J Neurosurg. 2005;103(2):284-8. 
http://dx.doi.org/10.3171/jns.2005.103.2.028
4 
 
74. Megerian CA, Haynes DS, Poe DS, Choo DI, 
Keriakas TJ, Glasscock ME 3rd. Hearing 
preservation surgery for small endolymphatic 
sac tumors in patients with von Hippel-Lindau 
syndrome. Otol Neurotol. 2002;23(3):378-87. 
http://dx.doi.org/10.1097/00129492-
200205000-00026 
 
75. Thompson LD. Endolymphatic sac tumor. 
Ear Nose Throat J. 2013;92(4-5):184-8. 
 
76. Butman JA, Kim HJ, Baggenstos M, 
Ammerman JM, Dambrosia J, Patsalides A, 
Patronas NJ, Oldfield EH, Lonser RR. 
Mechanisms of morbid hearing loss associated 
with tumors of the endolymphatic sac in von 
Hippel-Lindau disease. JAMA. 2007;298(1):41-
8. 
http://dx.doi.org/10.1001/jama.298.1.41 
 
77. Lonser RR, Kim HJ, Butman JA, Vortmeyer 
AO, Choo DI, Oldfield EH. Tumors of the 
endolymphatic sac in von Hippel-Lindau 
disease. N Engl J Med. 2004;350(24):2481-6. 
http://dx.doi.org/10.1056/NEJMoa040666 
 
78. Du J, Wang JM, Cui Y, Li GL. 
[Clinicopathologic features of endolymphatic sac 
tumor at cerebellopontine angle]. Zhonghua 
Bing Li Xue Za Zhi. 2011;40(9):590-4 (Chinese 
journal of pathology. 2011; 40(9): 590-4). 
 
79. Kempermann G, Neumann HP, Volk B. 
Endolymphatic sac tumours. Histopathology. 
1998;33(1):2-10. 
http://dx.doi.org/10.1046/j.1365-
2559.1998.00460.x 
 
80. Michaels L. Origin of endolymphatic sac 
tumor. Head Neck Pathol. 2007;1(2):104-11.  
http://dx.doi.org/10.1007/s12105-007-0016-3 
 
81. Andrew SM, Gradwell E. Immunoperoxidase 
labelled antibody staining in differential 
diagnosis of central nervous system 
haemangioblastomas and central nervous 
system metastases of renal carcinomas. J Clin 
Pathol. 1986;39(8):917-9. 
http://dx.doi.org/10.1136/jcp.39.8.917 
 
82. Gouldesbrough DR, Bell JE, Gordon A. Use 
of immunohistochemical methods in the 
differential diagnosis between primary cerebellar 
haemangioblastoma and metastatic renal 
carcinoma. J Clin Pathol. 1988;41(8):861-5. 
http://dx.doi.org/10.1136/jcp.41.8.861 
 
83. Vortmeyer AO, Weil RJ, Zhuang Z. 
Proteomic applications for differential diagnosis 
of histologically identical tumors. Neurology. 
2003;61(11):1626-7. 
http://dx.doi.org/10.1212/01.WNL.000009616
8.85260.60 
 
84. Hoang MP, Amirkhan RH. Inhibin alpha 
distinguishes hemangioblastoma from clear cell 
renal cell carcinoma. Am J Surg Pathol. 
2003;27(8):1152-6. 
http://dx.doi.org/10.1097/00000478-
200308000-00014 
 
85. Ingold B, Wild PJ, Nocito A, Amin MB, Storz 
M, Heppner FL, Moch H. Renal cell carcinoma 
marker reliably discriminates central nervous 
system haemangioblastoma from brain 
metastases of renal cell carcinoma. 
Histopathology. 2008;52(6):674-81. 
http://dx.doi.org/10.1111/j.1365-
2559.2008.03003.x 
 
86. Jung SM, Kuo TT. Immunoreactivity of 
CD10 and inhibin alpha in differentiating 
hemangioblastoma of central nervous system 
from metastatic clear cell renal cell carcinoma. 
Mod Pathol. 2005;18(6):788-94. 
http://dx.doi.org/10.1038/modpathol.3800351 
 
87. Roy S, Chu A, Trojanowski JQ, Zhang PJ. 
D2-40, a novel monoclonal antibody against the 
M2A antigen as a marker to distinguish 
hemangioblastomas from renal cell carcinomas. 
Acta Neuropathol. 2005;109(5):497-502. 
http://dx.doi.org/10.1007/s00401-005-0999-3 
 
88. Weinbreck N, Marie B, Bressenot A, 
Montagne K, Joud A, Baumann C, Klein O, 
Vignaud JM. Immunohistochemical markers to 
distinguish between hemangioblastoma and 
metastatic clear-cell renal cell carcinoma in the 
brain: utility of aquaporin1 combined with 
Vortmeyer et al.                                                                                             Nervous system in VHL syndrome 
 
Journal of Kidney Cancer and VHL 2015; 2(3):114-129.       http://jkcvhl.com  129 
 
cytokeratin AE1/AE3 immunostaining. Am J 
Surg Pathol. 2008;32(7):1051-9. 
http://dx.doi.org/10.1097/PAS.0b013e318160
9d7d 
 
89. Carney EM, Banerjee P, Ellis CL, Albadine 
R, Sharma R, Chaux AM, Burger PC, Netto GJ. 
PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in 
hemangioblastoma: A helpful combination in 
the differential diagnosis with metastatic clear 
cell renal cell carcinoma to the central nervous 
system. Am J Surg Pathol. 2011;35(2):262-7. 
http://dx.doi.org/10.1097/PAS.0b013e318206
4d11 
 
90. Jarrell ST, Vortmeyer AO, Linehan WM, 
Oldfield EH, Lonser RR. Metastases to 
hemangioblastomas in von Hippel-Lindau 
disease. J Neurosurg. 2006;105(2):256-63. 
http://dx.doi.org/10.3171/jns.2006.105.2.256 
 
91. Mottolese C, Stan H, Giordano F, Frappaz D, 
Alexei D, Streichenberger N. Metastasis of clear-
cell renal carcinoma to cerebellar 
hemangioblastoma in von Hippel Lindau 
disease: rare or not investigated? Acta Neurochir 
(Wien). 2001;143(10):1059-63. 
http://dx.doi.org/10.1007/s007010170012 
 
92. Sell S. Stem Cells and Cancer. New York: 
Springer, 2009. 
 
93. Grundmann E. [The concept of Julius 
Cohnheim on tumor formation and metastasis 
from the viewpoint of new research results]. 
Zentralbl Allg Pathol. 1985;130(4):323-31. 
 
94. Durante F. Nesso fisio-pathologico tra la 
struttura dei nei materni e la genesi di alcuni 
tumori maligni. Arch Memor Osser Chir Pract 
1874;11:217–226 
 
95. Bainbridge W. The cancer problem. New 
York: The Macmillan Company, 1918. 
 
96. Sell S. On the stem cell origin of cancer.  Am 
J Pathol. 2010;176(6):2584-494. 
http://dx.doi.org/10.2353/ajpath.2010.091064 
 
97. Shively SB, Falke EA, Li J, Tran MG, 
Thompson ER, Maxwell PH, Roessler E, Oldfield 
EH, Lonser RR, Vortmeyer AO.. Developmentally 
arrested structures preceding cerebellar tumors 
in von Hippel-Lindau disease. Mod Pathol. 
2011;24(8):1023-30. 
http://dx.doi.org/10.1038/modpathol.2011.61 
 
98. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, 
Oldfield EH. Developmental effects of von 
Hippel-Lindau gene deficiency. Ann Neurol. 
2004;55(5):721-8. 
http://dx.doi.org/10.1002/ana.20090 
 
99. Gläsker S, Sohn TS, Okamoto H, Li J, 
Lonser RR, Oldfield EH, Vortmeyer AO, Zhuang 
Z. Second hit deletion size in von Hippel-Lindau 
disease. Ann Neurol. 2006;59(1):105-10. 
http://dx.doi.org/10.1002/ana.20704 
 
100. Visvader JE. Cells of origin in cancer. 
Nature. 2011;469(7330):314-22. 
http://dx.doi.org/10.1038/nature09781 
 
101.Liu C, Chen Z, Chen Z, Zhang T, Lu Y. 
Multiple tumor types may originate from bone 
marrow-derived cells. Neoplasia. 2006;8(9):716-
24. 
http://dx.doi.org/10.1593/neo.06253 
 
102. Ratajczak MZ, Sellers ZP, Kucia M, Kakar 
SS. The embryonic rest hypothesis of cancer 
development - and old XIX century theory 
revisited. J Cancer Stem Cell Res 01/2014; 
1(1):1.  
http://dx.doi.org/10.14343/JCSCR.2014.1e10
01 
 
103. White AC, Lowry WE. Refining the role for 
adult stem cells as cancer cells of origin. Trends 
Cell Biol. 2015;25(1):11-20. 
http://dx.doi.org/10.1016/j.tcb.2014.08.008 
 
 
 
 
 
 
 
